



M 3999M

**DEPARTMENT OF HEALTH & HUMAN SERVICES**  
Public Health Service  
**Food and Drug Administration**  
SOUTHWEST REGION

Office of the Regional  
Food and Drug Director  
7920 Elmbrook Drive, Suite 102  
Dallas, TX 75247-4982  
TELEPHONE: 214-655-8100  
FACSIMILE: 214-655-8130

July 11, 2000

**WARNING LETTER**

**CERTIFIED MAIL**  
**RETURN RECEIPT REQUESTED**

00-SWR-WL-70/7

Mona Martinez  
Administrative Director  
Irving Women's Imaging Center  
2001 N. McArthur, Suite 250  
Irving, TX 75061

RE: Inspection ID - 1526370006

Dear Ms. Martinez,

On July 6, 2000 a representative from the state of Texas, acting on behalf of the Food and Drug Administration (FDA) inspected your facility. This inspection revealed a serious regulatory problem involving the mammography at your facility.

The Mammography Quality Standards Act of 1992 requires your facility to meet specific standards. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following level 1 and level 2 findings at your facility:

Level 1: Mammograms were processed in processor 1, Kodak, RP X-OMAT, when it was out of limits on 5 days.

Level 2: A medical physicist's survey has not been conducted for x-ray unit 2, Siemens Medical Systems, room 214 / 3 within the last 14 months.

Level 2: Corrective actions for processor QC failures were not documented at least once for processor 1, Kodak, RP X-OMAT.

Level 2: The mammography equipment evaluation [by a medical physicist] for unit 2, Siemens Medical Systems, room 214 / 3, or related processor were not done.

The specific problems noted above appeared on your MQSA Facility Inspection Report, which was issued to your facility at the close of the inspection.

Level 1 findings may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility. They represent a serious violation of the law, which may result in FDA taking regulatory action without further notice. These actions include, but are not limited to:

- Placing your facility under a Directed Plan of Correction.
- Charging your facility for the cost of on-site monitoring.
- Assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the Standards.
- Suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against further mammography.

It is necessary for you to act on this matter immediately. You are required to respond to this office in writing within fifteen (15) working days from receipt of this letter. Please address the following:

- The specific steps you have taken to correct all of the violations noted in this letter.
- Each step your facility is taking to prevent the recurrence of similar violations.
- Equipment settings (including technique factors), raw test data, and calculated final results where appropriate.
- Sample records that demonstrate proper record keeping procedures, if the findings relate to quality control or other records (Note: Patient names or identification should be deleted from any copies submitted).

Please submit your response to:  
Deborah M. McGee, Radiation Specialist  
Food and Drug Administration  
7920 Elmbrook Drive, Suite 102  
Dallas, TX 75247-4982

This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at <http://www.fda.gov>.

If you have more specific questions about mammography facility requirements, or about the content of this letter, please feel free to contact Ms. McGee at (214) 655-8100, extension 138.

Sincerely,

A handwritten signature in black ink, appearing to read "Darryl Brown". The signature is fluid and cursive, with a long horizontal stroke extending from the end.

Darryl Brown  
Acting Regional Food and Drug Director